Here is why ASX healthcare shares ANR and AHI are trending today

Summary

  • Anatara Lifesciences provided an update on its clinical trial activities for Gastrointestinal Re-Programming (GaRP) and psychological functioning trials.
  • Advanced Human Imaging has entered into an agreement with INTER-PSY BV (Inter-Psy) for the integration of its CompleteScan.

The ASX200 index was marginally up at 7182.70 points with Resolute Mining (ASX:RSG) and Pro Medicus (ASX:PME) among the top gainers (At AEST 11:31 AM).

Two Australian healthcare shares - Anatara Lifesciences (ASX:ANR) and Advanced Human Imaging Limited (ASX:AHI) – have come up with key announcements today that could potentially have an impact on their respective share price. At AEST 11:35 AM, AHI shares were trading 2.564% higher at AU$1.600 while ANR shares were flat at AU$0.175.

Some other ASX-listed healthcare shares doing well today morning include Actinogen Medical Limited (ASX:ACW), BOD Australia Limited (ASX:BDA), Austco Healthcare Limited (ASX:AHC) and Immutep Ltd (ASX:IMM).

ALSO READ: ASX 200 on Monday: Top five things to watch out for

Let’s now discuss the updates of ANR and AHI in detail-

Anatara progressing towards first human clinical studies

A developer of evidence-based solutions, Anatara Lifesciences, has provided the update on its clinical trial activities for Gastrointestinal Re-Programming (GaRP) trial and targeted delivery formulation (3FDC) trial.

The Company stated that it anticipates the launch of the Gastrointestinal Re-Programming (GaRP) trial recruitment website and screening of subjects for enrolment within the next two weeks. Recruitment for Phase 1 of this clinical trial is likely to be completed in December 2021.  

Copyright © 2021 Kalkine Media

The Company also disclosed that targeted delivery formulation (3FDC) clinical trial is for the evaluation of assessing psychological functioning.  Additionally, the CSIRO team will develop the guidelines and commence recruitment for psychological functioning trial with the aim of administering dose to the first participants in Q3 CY21. Anatara anticipates commencing screening of volunteers for this trial in August 2021.

Steve Lydeamore, CEO of Anatara, commented-

AHI Signs agreement with Inter-Psy to integrate CompleteScan

Advanced Human Imaging has entered into an agreement with INTER-PSY BV, a Netherlands-based mental health and addiction care firm. With this agreement, AHI will integrate its CompleteScan into Inter-Psy’s Health i Check platform. Health i Check platform is developed by Inter-Psy and is a preventative health screening app to be marketed in the Dutch and European markets.

On the finalisation of the integration with AHI, Inter-Psy aims to offer the combined Health i Check to the remaining European nations. The companies plan to launch Health i Check in the Netherlands in June 2021.

Copyright © 2021 Kalkine Media

AHI’s technology would be integrated into the Health i Check platform for an October 2021 release. With the terms of the agreement, Inter-Psy will use its top endeavours and target almost 200K active customers on the Health i Check within the initial 12 months.

GOOD READ: Three ASX healthcare shares on the rise today – AHI, PCK, 4DX


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   

Kalkine

Rated 4.3/5 based on 904 Reviews at Google My Business
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK